
About Intima Bioscience
Intima Bioscience is a Healthcare company based in New York (United States) founded in 2014. Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing. Intima Bioscience offers products and services including Checkpoint Cell Therapy and Tumor Infiltrating Lymphocytes (TIL). Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is Intima Bioscience, Inc. Similar companies include eGenesis, Beam Therapeutics and Korro Bio; 3 of its 3 listed similar companies have raised funding.
Company details
Intima Bioscience was founded in 2014 in New York, United States, within the biotechnology sector. A gene and cell therapeutic platform is being developed for gastrointestinal cancer treatment. Clinical trials are underway, with experiments conducted via the Molecular and Cell Therapy (MCT) GMP manufacturing platform. CRISPR technology is employed to engineer neoantigen-specific tumor-infiltrating lymphocytes that inhibit the intracellular immune checkpoint CISH.
- Headquarters New York, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website intimabioscience.com
- Legal Name Intima Bioscience, Inc
Products & Services of Intima Bioscience
Intima Bioscience offers a comprehensive portfolio of products and services, including Checkpoint Cell Therapy and Tumor Infiltrating Lymphocytes (TIL).
Uses CRISPR to edit T cells for inhibiting immune checkpoints in cancers
Genetically engineered lymphocytes for treating solid tumor cancers
Similar companies to Intima Bioscience
Intima Bioscience has 3 listed similar companies in our database, 3 of them funded. They include eGenesis, Beam Therapeutics and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed similar companies of Intima Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Intima Bioscience
The website of Intima Bioscience (intimabioscience.com) receives about 3K visits a month.
- Monthly visits3K
▲ 496.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Intima Bioscience (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intima Bioscience
Complete news archive for Intima Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intima Bioscience
Intima Bioscience was founded in 2014.
Intima Bioscience is headquartered in New York, United States. It is registered at New York, New York, United States.
Intima Bioscience was founded in 2014 in New York, United States, within the biotechnology sector. A gene and cell therapeutic platform is being developed for gastrointestinal cancer treatment. Clinical trials are underway, with experiments conducted via the Molecular and Cell Therapy (MCT) GMP manufacturing platform. CRISPR technology is employed to engineer neoantigen-specific tumor-infiltrating lymphocytes that inhibit the intracellular immune checkpoint CISH.
Intima Bioscience's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Intima Bioscience offers Checkpoint Cell Therapy and Tumor Infiltrating Lymphocytes (TIL).
Intima Bioscience operates through Intima Bioscience, Inc.
